Crohn's disease: A review of treatment options and current research

Cellular Immunology

Volumn 286, Issue 1-2, 2013, Pages 45-52

  Bandzar, Sean ^a   Gupta, Shabnam ^b   Platt, Manu O ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Crohn's disease; TNF alpha blocker

Indexed keywords

ABATACEPT; ACTEMERIA; ADALIMUMAB; ALPHA4 INTEGRIN; AMG 139; BE 8; BRODALUMAB; CERTOLIZUMAB PEGOL; CONJUGATED LINOLEIC ACID; GAMMA INTERFERON; HUMAN GROWTH HORMONE; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; NURION; ORENICIA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RIFAXIMIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; USTEKINUMAB; VISILIZUMAB;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HORMONAL THERAPY; HUMAN; INTRACELLULAR SIGNALING; LEUKOCYTE MIGRATION INHIBITION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENT INFECTION; REVIEW; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; UPREGULATION;

CROHN'S DISEASE; DC; DENDRITIC CELL; IL; INTERLEUKIN; TNF; TNF-ALPHA BLOCKER; TUMOR NECROSIS FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; CYTOKINES; DISEASE MANAGEMENT; GASTROINTESTINAL AGENTS; HUMANS; INTEGRIN ALPHA4; JANUS KINASE 2; LINOLEIC ACIDS, CONJUGATED; PALLIATIVE CARE; RIFAMYCINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890096310     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.11.003     Document Type: Review

References (89)

1. Anonymous, Crohn's and colitis foundation of America, explore CCFA research (2010). Available from: <>. http://www.ccfa.org/research/?LMI=7.
2. Mayo Clinic Staff, Mayo Clinic, Crohn's disease: Symptoms. Available from: <>. http://www.mayoclinic.com/health/crohnsdisease/DS00104/DSECTION=symptoms.
3. Farmer R.G., Hawk W.A., Turnbull R.B. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975, 68:627-635.
4. Molnar T., Tiszlavicz L., et al. Clinical significance of granuloma in Crohn's disease. World J. Gastroenterol. 2005, 20:3118-3121.
5. Maglinte D., Gourtsoyiannis N., et al. Classification of small bowel Crohn's subtypes based on multimodality imaging. Radiol. Clin. North Am. 2003, 41:285-303.
6. Hvas C.L., Dahlerup J.F., et al. Diagnosis and treatment of fistulising Crohn's disease. Danish Med. J. 2011, 58:C4338.
7. Evans P.E., Pardi D.S. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. Med. Gen. Med. 2007, 9:55.
8. Schall J., Semeao E., Stallings V. Self-assessment of sexual maturity status in children with Crohn's disease. J. Pediatr. 2002, 141:223-229.
9. Roggenbuck D., Hausdorf G., et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009, 58:1620-1628.
10. Carol M., Borruel N., Antolin M., et al. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc. Biol. 2006, 79:917-922.
11. Itoh J., de la Motte C., Strong S., et al. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001, 49:35-41.
12. Muller A., Lamprecht P. Interleukin-17 in chronic inflammatory and autoimmune diseases: rheumatoid arthritis, Crohn's disease and Wegener's granulomatosis. Zeitschrift für Rheumatologie 2008, 67:72-74.
13. Fuss I.J., Becker C., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 2006, 12:9-15.
14. Ruemmele F., Prieur A., Talbotec C., et al. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J. Pediatr. Gastroenterol. Nutr. 2004, 39:203-206.
15. Honey K. The comeback kid: Tysabri now FDA approved for Crohn's disease. J. Clin. Invest. 2008, 118:825-826.
16. Panes J., Gomollon F., Taxonera C., et al. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007, 67:2511-2537.
17. Otley A., Critch J., Butzner J. Infliximab for the treatment of paediatric Crohn's disease: obstacles to accessing a necessary therapy. J. Paediatr. Child Health 2004, 9:87-89.
18. Welch B. Adalimumab (Humira) for the treatment of rheumatoid arthritis. Am. Fam. Phys. 2008, 78:1406-1408.
19. Johnson and Johnson pharmaceutical research and development. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <> NLM Identifier: NCT01369355. http://clinicaltrials.gov/show/NCT01369355.
20. Amgen. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <> NLM Identifier: NCT01150890. http://clinicaltrials.gov/show/NCT01150890.
21. Amgen. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <> NLM Identifier: NCT01258205. http://clinicaltrials.gov/show/NCT01258205.
22. Hiroaki I., Masakazu T., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 125:989-996.
23. Mannon P., Fuss I., et al. Anti-interleukin-12 antibody for active Crohn's disease. New Engl. J. Med. 2004, 351:2069-2079.
24. Herrero-Beaumont G., Calatrava M.J.M., Castaneda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatologia Clinica 2012, 8:78-83.
25. Sandborn W.J., Colombel J.F., Frankel M., et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010, 59:1485-1492.
26. Schreiber S., Fedorak R.N., Nielsan O.H., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000, 119:1461-1472.
27. Van Deventer S., Elson C., Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid- refractory Crohn's disease. Gastroenterology 1997, 113:289-383.
28. Autschbach F., Braunstein J., Helmke B., et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 1998, 153:121-130.
29. Buruiana F.E., SolàI Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2010, CD005109.
30. Herrlinger K.R., Witthoeft T., Raedler A., et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol. 2006, 101:793-797.
31. Sands B.E., Bank S., Sninsky C.A., et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999, 117:58-64.
32. Scrascia M., Forcillo M., Maimone F., et al. Susceptibility to rifaximin of Vibrio Cholerae strains from different geographical area. J. Antimicrob. Chemother. 2003, 52:303-305.
33. Charmot D. Non-systemic drugs: a critical review. Curr. Pharm. Des. 2012, 18:1434-1445.
34. Shafran I., Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig. Dis. Sci. 2010, 4:1079-1084.
35. Scarpignato C., Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005, 51:36-66.
36. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr. Pharm. Des. 2003, 9:295-305.
37. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 2007, 13:1323-1332.
38. Murray J., Barbara J., et al. Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirements for TNF-R55 and TNF-R75 for induction of apoptosis in vitro. Blood 1997, 90:2772-2783.
39. Ebert E. Infliximab and the TNF-alpha system. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 296:G612-G620.
40. Present D., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New Engl. J. Med. 1999, 340:1398-1405.
41. Reinhard C., Shamoon B., Shyamala V., et al. Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2. The EMBO J. 1997, 16:1080-1092.
42. Cvetkovic R., Scott L. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs 2006, 20:293-311.
43. Vena G., Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics 2007, 1:93-103.
44. Hughes B. 2008 FDA drug approvals. Nat. Rev. Drug Dis. 2008, 8:93-96.
45. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004, 53:70-77.
46. Zidi I., Mnif W., Bouaziz A., et al. Certolizumab pegol therapy for rheumatoid arthritis: overview. Drug Dev. Res. 2011, 72:603-614.
47. Rice G., Hartung H.P., et al. Anti-alpha 4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 65:1336-1342.
48. Ferguson T.A., Mizutani H., et al. Two integrin binding peptides abrogate T-cell mediated immune responses in vivo. Proc. Natl. Acad. Sci. 1991, 88:8072-8076.
49. Chan P.Y., Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J. Biol. Chem. 1993, 268:24655-24664.
50. Hickey M., Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat. Rev. Immunol. 2009, 9:364-375.
51. Gottlieb A. Infliximab for psoriasis. J. Am. Acad. Dermatol. 2003, 49:112-117.
52. Karppinen J., Korhonen T., Malmivaara A., et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003, 28:750-753.
53. Sandborn W., Feagan B., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. New Engl. J. Med. 2007, 357:228-238.
54. Scheinfeld N. Adalimumab (Humira): a brief review for dermatologists. J. Dermatol. Treat. 2004, 15:348-352.
55. Ransohoff R. Natalizumab for multiple sclerosis. New Engl. J. Med. 2007, 356:2622-2629.
56. Clifford D., De Luca A., Simpson D., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446.
57. Baumgart D.C., Lowder J.N., Targan S.R., et al. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol. 2009, 104:868-876.
58. Sandborn W.J., Colombel J.F., Sands B.E., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012, 143:62-69.
59. Ghannem S., Pene J., Torcy-Moquet G., et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185:302-312.
60. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
61. Duijvestein M., Vos A.C., Roelofs H., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
62. Ciccocioppo R., Bernardo M.E., Sgarella A., et al. A phase I clinical trial of the treatment of Crohn's disease. Gut 2011, 60:788-798.
63. Panes J., Benitez-Ribas D., Salas A. Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?. Gut 2011, 60:742-744.
64. Denson L., Kim M., Bezoid R., et al. A randomized controlled trial of growth hormone in active pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2010, 51:130-139.
65. Bassaganya-Riera J., Hontecillas R., Horne W., et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin. Nutr. 2012, 31:721-727.
66. Lee S, Induction of clinical response using rifaximin in Crohn's disease. ClinicalTrials.gov. Natl. Lib. Med. (2012). Available from: <> NLM Identifier: NCT00603616. http://clinicaltrials.gov/show/NCT00603616.
67. Sandborn W.J., Gasink C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New Engl. J. Med. 2012, 367:1519-1528.
68. Targan S.R., Feagan B.G., et al. Mo2083 a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 2012, 143:26.
69. Nishimoto M. Interleukin-6 as a therapeutic target in candidate inflammatory disease. Clin. Pharmacol. Ther. 2010, 87:483-487.
70. Drug enforcement administration human growth hormone (2011). Available from: <>. http://www.deadiversion.usdoj.gov/drugs_concern/hgh.pdf.
71. Wells J. Binding in the growth hormone receptor complex. Proc. Natl. Acad. Sci. USA 1996, 93:1-6.
72. Zych S., Szatkowska I., Czerniawska-Piatkowska E. Growth hormone signaling pathways. Postepy Biochem. 2006, 52:367-372.
73. Walters T., Griffiths A. Mechanisms of growth impairment in pediatric Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:513-523.
74. Calenda K., Schornagel I., Sadeghi-Nejad A., et al. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm. Bowel Dis. 2005, 11:435-441.
75. Langenheim J., Chen W. Improving the pharmacokinetics/ pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J. Endocrinol. 2009, 203:375-387.
76. González L., Curto L., Miquet J., et al. Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver. Growth Horm. IGF Res. 2007, 17:104-112.
77. Fisker S. Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects. Growth Horm. IGF Res. 2006, 16:1-28.
78. Haffner D., Schaefer F., Girard J., et al. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J. Clin. Investig. 1994, 93:1163-1171.
79. Hizuka N., Gorden P., Maxine A., et al. Polypeptide hormone degradation and receptor regulation are coupled to ligand internalization. A direct biochemical and morphologic demonstration. J. Biol. Chem. 1981, 256:4591-4597.
80. Wong S.C., Kumar P., et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin. Endocrinol. 2011, 74:599-607.
81. Wong S.C., Hassan K., et al. Effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J. Pediatr. Endocrinol. Metab. 2007, 20:1315-1324.
82. Belli D.C., Seidman E., et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988, 94:603-610.
83. A. Slonim, Growth hormone and exclusion diet in Juvenile Crohn's disease. ClinicalTrials.gov. Natl. Lib. Med. (2012). Available from: <> NLM Identifier: NCT01647412. http://clinicaltrials.gov/show/NCT00603616.
84. Slonim A.E., Grovit M., et al. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J. Am. Coll. Nutr. 2009, 28:277-285.
85. O'Quinn P., Nelssen J., Goodband R., et al. Conjugated linoleic acid. Anim. Health Res. Rev. 2000, 1:35-46.
86. Huebner S., Campbell J., Butz D., et al. Individual isomers of conjugated linoleic acid reduce inflammation associated with established collagen-induced arthritis in DBA/1 mice. J. Nutr. 2010, 140:1454-1461.
87. Evans N., Misyak S., Schmelz E., et al. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPAR-gamma. J. Nutr. 2010, 140:515-521.
88. Davies P., Bailey P., Goldenberg M., et al. The role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol. 1984, 2:335-357.
89. Whigham L., Cook E., Stahl J., et al. CLA reduces antigen-induced histamine and PGE2 release from sensitized guinea pig trachaea. Am. J. Physiol. Regul. Integ. Comp. Physiol. 2000, 280:R908-R912.